Treatment of fibrocystic disease of the breast with gestrinone, a new trienic synthetic steroid with anti-estrogen, anti-progesterone properties
| Autor: | G. Azadian-Boulanger, Elsimar Metzker Coutinho |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Adult
Gestrinone medicine.medical_specialty Adolescent medicine.medical_treatment Anti estrogen Asymptomatic Steroid Recurrence medicine Humans Fibrocystic Breast Disease Progesterone Acne Clinical Trials as Topic business.industry Estrogen Antagonists Obstetrics and Gynecology Nodule (medicine) General Medicine medicine.disease Fibrocystic disease Surgery Norpregnatrienes Female medicine.symptom business Weight gain Follow-Up Studies Mammography medicine.drug |
| Zdroj: | International Journal of Gynecology & Obstetrics. 22:363-366 |
| ISSN: | 0020-7292 |
| DOI: | 10.1016/0020-7292(84)90067-5 |
| Popis: | Twenty-eight patients with radiologically diagnosed fibrocystic disease were given twice weekly 5 mg tablets of Gestrinone, a synthetic contraceptive steroid with potent anti-estrogen, anti-progesterone properties, for periods ranging from 3 to 9 months. Treatment was discontinued when the nodularity disappeared and the patient became asymptomatic. Twelve patients had palpable nodules or masses in both breasts, while the remaining 16 had a single nodule or lump. In 12 patients, all with small nodules or lumps, complete elimination of nodularity occurred at the end of the first 3 months of treatment. In a further eight patients, five of whom had small nodules and three of whom had large ones, an additional 3 months of therapy were required to achieve complete elimination of nodularity. In two subjects, nodularity was eliminated at the end of 9 months of therapy, and in the remaining six subjects, although a reduction in nodularity greater than 50% occurred, masses remained palpable at the end of 9 months. Pain and tenderness were eliminated during the first 2 weeks of therapy in most cases. The most common complaints were acne and seborrhea (70% of patients) and a weight gain of between 2 and 5 kg in patients treated for 9 months. Main side effects encountered were acne and seborrhea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text